May 22nd 2025
FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.
FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115
January 4th 2024The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.